GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » Total Equity

Cereno Scientific AB (OSTO:CRNO B) Total Equity : kr191.93 Mil (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cereno Scientific AB Total Equity?

Cereno Scientific AB's total equity for the quarter that ended in Dec. 2024 was kr191.93 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cereno Scientific AB Total Equity Historical Data

The historical data trend for Cereno Scientific AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB Total Equity Chart

Cereno Scientific AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.74 170.07 201.51 216.42 191.93

Cereno Scientific AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 216.42 200.99 253.49 230.73 191.93

Cereno Scientific AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cereno Scientific AB's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=413.772-221.846
=191.93

Cereno Scientific AB's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=413.772-221.846
=191.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cereno Scientific AB Total Equity Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cereno Scientific AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » Total Equity
Comparable Companies
OSTO:EQL OSTO:ENZY OSTO:DICOT OSTO:ORX OSTO:CINPHA OSTO:MOB OSTO:NANEXA OSTO:ERMA OSTO:KLAR XSAT:ACUC ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
4A1:Germany
Address
BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83
Website
https://www.cerenoscientific.se
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines